Equity Profile

BMY

Bristol-Myers Squibb Company

Health CarePharmaceuticals$132.1B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Bristol-Myers Squibb Company (BMY) is a leading pharmaceutical company that focuses on discovering, developing, and delivering innovative medicines for serious diseases. As a key player in the health care sector, its advancements in treatments can significantly impact patient care and the pharmaceutical market.

Key Metrics to Watch

EPS

Earnings per share is a critical measure of profitability, and investors will be keen to see if BMY meets or exceeds expectations.

$1.66

Revenue

Total revenue gives insight into the company's sales performance and market demand for its products.

$12.4B

Wall Street expectations, options signals, track record, and call prep available with Pro.

BMY Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+12.21%

Avg Stock Reaction

+2.95%

Last Quarter Recap

In Q1-2026, Bristol-Myers Squibb reported an EPS of $1.58, surpassing estimates by 9.65%. The stock reacted positively, gaining over 5% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about BMY's upcoming earnings, expecting it to meet or slightly exceed EPS and revenue estimates.

Bull Case

If BMY can deliver strong sales growth and maintain its profitability, it could reinforce investor confidence and lead to a stock price increase.

Bear Case

Conversely, any signs of declining sales or profitability could raise concerns about the company's future growth prospects, potentially leading to a stock price drop.

Key Metrics to Watch

EPS

$1.66

Earnings per share is a critical measure of profitability, and investors will be keen to see if BMY meets or exceeds expectations.

Revenue

$12.4B

Total revenue gives insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will BMY's EPS meet or exceed the consensus estimate of $1.66?

A strong EPS could indicate solid profitability and boost investor confidence, while a miss could raise concerns.

What are the revenue figures relative to the expected $12.4 billion?

Revenue performance will provide insights into the demand for BMY's products and overall market health.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate BMY's potential for revenue growth due to strong demand for its key products, which could lead to an EPS surprise.

Supporting Evidence

BMY has consistently beaten EPS estimates in recent quarters, suggesting strong operational performance.

The options market is pricing a move that aligns with historical averages, indicating potential for a larger reaction than expected.

Key Risk

If revenue comes in significantly above $12.4 billion, it could challenge the current consensus and lead to a re-evaluation of growth expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating BMY's ability to sustain its growth trajectory amidst competitive pressures and market dynamics.

Bull Confirmed If

An EPS of $1.70 or higher, with revenue exceeding $12.8 billion, would confirm the bull case.

Bear Confirmed If

An EPS below $1.60 and revenue under $12 billion would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±4.83%

Historical Avg

±5.36%

In line with history

The options market is pricing in a moderate move around the earnings report, suggesting that investors are anticipating some volatility.

Options are pricing a 4.83% move, which is in line with the stock's historical average move of 5.36%.

Detail

ATM IV

0.3%

30d HV

25.7%

Calls (1.0M)P/C Ratio: 1.07Puts (2.8M)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BMY beats expectations, history suggests a potential stock increase of around 4.21%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the market may react cautiously, leading to minimal movement in the stock price.

Miss

A miss could result in a decline of approximately 5.81%, reflecting investor disappointment and concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug approvals or pipeline developments.
2Insights into market demand for key products and any changes in competitive dynamics.
3Management's outlook on future revenue growth and profitability.
4Comments on cost management and operational efficiency improvements.
5Any guidance on upcoming product launches or strategic initiatives.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a critical measure of profitability, and investors will be keen to see if BMY meets or exceeds expectations.

$1.66

Revenue

Total revenue gives insight into the company's sales performance and market demand for its products.

$12.4B

Wall Street expectations, options signals, track record, and call prep available with Pro.

BMY Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+12.21%

Avg Stock Reaction

+2.95%

Last Quarter Recap

In Q1-2026, Bristol-Myers Squibb reported an EPS of $1.58, surpassing estimates by 9.65%. The stock reacted positively, gaining over 5% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about BMY's upcoming earnings, expecting it to meet or slightly exceed EPS and revenue estimates.

Bull Case

If BMY can deliver strong sales growth and maintain its profitability, it could reinforce investor confidence and lead to a stock price increase.

Bear Case

Conversely, any signs of declining sales or profitability could raise concerns about the company's future growth prospects, potentially leading to a stock price drop.

Key Metrics to Watch

EPS

$1.66

Earnings per share is a critical measure of profitability, and investors will be keen to see if BMY meets or exceeds expectations.

Revenue

$12.4B

Total revenue gives insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will BMY's EPS meet or exceed the consensus estimate of $1.66?

A strong EPS could indicate solid profitability and boost investor confidence, while a miss could raise concerns.

What are the revenue figures relative to the expected $12.4 billion?

Revenue performance will provide insights into the demand for BMY's products and overall market health.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate BMY's potential for revenue growth due to strong demand for its key products, which could lead to an EPS surprise.

Supporting Evidence

BMY has consistently beaten EPS estimates in recent quarters, suggesting strong operational performance.

The options market is pricing a move that aligns with historical averages, indicating potential for a larger reaction than expected.

Key Risk

If revenue comes in significantly above $12.4 billion, it could challenge the current consensus and lead to a re-evaluation of growth expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating BMY's ability to sustain its growth trajectory amidst competitive pressures and market dynamics.

Bull Confirmed If

An EPS of $1.70 or higher, with revenue exceeding $12.8 billion, would confirm the bull case.

Bear Confirmed If

An EPS below $1.60 and revenue under $12 billion would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±4.83%

Historical Avg

±5.36%

In line with history

The options market is pricing in a moderate move around the earnings report, suggesting that investors are anticipating some volatility.

Options are pricing a 4.83% move, which is in line with the stock's historical average move of 5.36%.

Detail

ATM IV

0.3%

30d HV

25.7%

Calls (1.0M)P/C Ratio: 1.07Puts (2.8M)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BMY beats expectations, history suggests a potential stock increase of around 4.21%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the market may react cautiously, leading to minimal movement in the stock price.

Miss

A miss could result in a decline of approximately 5.81%, reflecting investor disappointment and concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug approvals or pipeline developments.
2Insights into market demand for key products and any changes in competitive dynamics.
3Management's outlook on future revenue growth and profitability.
4Comments on cost management and operational efficiency improvements.
5Any guidance on upcoming product launches or strategic initiatives.